Monopar Therapeutics Co-Founder and CSO Dr. Andrew Mazar resigns effective April 8, 2022

Monopar Therapeutics

Dr. Andrew P. Mazar resigns as EVP of R&D, Chief Scientific Officer, and Board member.
Resignation effective April 8, 2022; no replacement announced.
Dr. Mazar was a Co-Founder of the company.
Monopar's common stock trades on Nasdaq under ticker MNPR.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Andrew P. Mazar

Chief Scientific Officer

MNPR · Monopar Therapeutics

Effective: 2022-04-08
Filed: April 1, 2022, 7:59 PM ET

Dr. Andrew P. Mazar, the Company’s Co-Founder, Executive Vice President of Research and Development, Chief Scientific Officer and Board Member, will be resigning from his position with the Company and as a member of the Company’s Board of Directors effective April 8, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Andrew P. Mazar departed as Chief Scientific Officer at Monopar Therapeutics.

Action: resigning
Role: Chief Scientific Officer

Exact text from the filing

Dr. Andrew P. Mazar, the Company’s Co-Founder, Executive Vice President of Research and Development, Chief Scientific Officer and Board Member, will be resigning from his position with the Company and as a member of the Company’s Board of Directors effective April 8, 2022.

View on SEC.gov

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001654954-22-004477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.